Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD0865 · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| AZD0865 | DRUG | - |
Inclusion Criteria: * Identification of their main symptom as heartburn defined as a burning feeling behind the breastbone. * Have at least a 6-month history of heartburn and at least 4 days of episodes of heartburn with at least overall moderate intensity during the last 7 days prior to visit 1. *...
AZD0865 is an investigational small molecule being developed for gastroesophageal reflux disease (GERD), specifically for GERD with erosive esophagitis and GERD without erosive esophagitis. It is in Phase 2 clinical development and is not yet approved by regulatory authorities.
AZD0865 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The drug is currently in Phase 2 clinical trials for the treatment of gastroesophageal reflux disease.
AZD0865 is in Phase 2 clinical development. It has completed two Phase 2b dose-finding studies in patients with GERD, one with erosive esophagitis and one without erosive esophagitis. The drug remains investigational and has not been approved.
AZD0865 has completed two Phase 2b clinical trials. NCT00206245 studied the drug in GERD patients with erosive esophagitis, and NCT00206284 studied it in GERD patients without erosive esophagitis. Both trials were randomized, double-blind, and enrolled a total of 1400 participants across multiple countries.
AZD0865 is a small molecule designed to treat gastroesophageal reflux disease by reducing gastric acid secretion. It is being investigated for its ability to heal erosive esophagitis and relieve symptoms in patients with non-erosive reflux disease, though its specific molecular target has not been disclosed.